Dupixent Market (By Indication: Atopic Dermatitis AD, Asthma, Chronic Rhinosinusitis With Nasal Polyps CRSwNP, Chronic Obstructive Pulmonary Disease COPD; By: Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2025-2034

Dupixent Market Size and Top Companies 

The dupixent market size was worth USD 14.18 billion in 2024 and is estimated to reach USD 15.29 billion in 2025 to approximately USD 30.05 billion by 2034, growing at a CAGR of 7.8% over the forecast period. The increasing inflammatory diseases, strong market position and efficacy, and continuous rollout in new markets, particularly in rapidly growing regions with improving healthcare infrastructure. The increased physician and patient awareness, rising prevalence of Type 2 inflammatory disease, drive the market growth. 

Key Pointers

• By region, North America dominated the global market with highest share of 77% in 2024. Due to the high demand.
• By region, Asia Pacific the market is expected to grow at the notable CAGR during the forecast period. Due to rapid expansion.
• By indication, the atopic dermatitis segment captured the maximum market share of 74% in 2024. Due to increasing demand.
• By indication, the chronic obstructive pulmonary disease segment is predicted to grow at the remarkable CAGR from 2025 to 2034. Increasing cases.
• By Distribution Channel hospital pharmacies segment is contributed the largest market share of 54% in 2024. Due to its various applications. 
• By distribution channel, the others segment is estimated to expand the fastest CAGR during the forecast period. The increasing accessibility. 

Report Scope of the Dupixent Market

Dupixent Market Overview 

The Dupixent market is a biologic prescription medicine that works as a monoclonal antibody targeted interleukin-4 and interleukin-13 pathways, which are key drivers of type-2 inflammation. The market growth is driven by the rising disease prevalence higher rate of chronic conditions creates greater demand for treatments. The increasing aging population, elderly populations need more medications, boosting pharmaceutical consumption. The increasing disposable income and healthcare access in the Asia Pacific, Latin America create new demand. The innovations in biologics, gene therapy, and AI-driven drug discovery expand treatment possibilities and drive market growth.

Rising Prevalence of Atopic and Inflammatory Diseases Market Growth.

The growth of the Dupixent market is primarily driven by the increasing prevalence of chronic inflammatory diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. As these conditions continue to affect millions worldwide, there is a growing demand for effective, long-term treatment solutions. Dupixent’s targeted mechanism of action and proven efficacy in reducing symptoms and improving patients’ quality of life have made it a preferred choice among healthcare providers.

The diseases, such as atopic dermatitis, asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps, are rising globally, driving the need for effective long-term therapies. The traditional treatment option often provides limited efficacy, positioning Duplixent as a preferred choice. The FDA approved Duplixent for eosinophilic esophagitis, making it the first treatment for this condition and expanding its market potential.

What are the Trends in Dupixent Market? 

• Broadening Therapeutic Indications: The Dupixent approval for treating conditions such as Chronic Obstructive Pulmonary Disease (COPD) is a major growth driver, opening up a large, previously untapped patient population. The general market trend away from traditional treatments towards more targeted biologics, and Dupixent, as a biologic, benefits from this shift.
• In April 2025, the FDA approved Dupixent for adults and adolescents aged 12 and older with CSU that remains symptomatic despite antihistamine treatment. (Source: Dermatology TIMES)
  

Market Opportunity

Growth in the COPD for the Dupixent Market

The treatment options for COPD have been limited to inhaled medicines. Many patients with severe disease, particularly those with a type 2 inflammatory phenotype, continue to experience frequent exacerbations despite being on maximal standard-of-care inhaled therapy. Dupixent directly addresses this gap.
In June 2025, the FDA approval of GSK's Nucala (mepolizumab) for eosinophilic chronic obstructive pulmonary disease (COPD) introduces a new, targeted competitor for Dupixent in the lucrative Type 2 inflammatory respiratory market. (Source: Pulmonology ADVISOR)

Market Challenge

High Cost of Treatment of the Dupixent Market

The premium biologic drug, Dupixent, carries a high price point. This can make it unaffordable for patients, particularly in regions with limited health insurance coverage. Payer organizations, both public and private, exert pricing pressures and require robust cost-effectiveness data before approving coverage. Even with coverage, high co-payments can pose a financial burden for patients.

Which Region Dominates the Dupixent Market?

North America dominated the Dupixent market in 2024, accounting for the largest share of 77% in 2024. The high incidence of dermatitis, asthma, and other related conditions in the region is, major key player in the region. There is a growing trend among U.S. physicians to prescribe targeted biologic therapies like Dupixent instead of traditional, less effective options with more side effects, such as long-term systemic corticosteroids, which can significantly contribute to market share. 

United States Dupixent Market Trends

The rising acceptance of biological treatments and  growing patient population with chronic inflammatory conditions contribute to market growth. The FDA continues to approve Dupixent for additional conditions, broadening its patient base. Recent approvals. The growing prevalence of type-2 inflammatory diseases and high customer and physician satisfaction.

• In June 2025, the US Food and Drug Administration (FDA) approved Dupixent (dupilumab) to treat adult patients with bullous pemphigoid (BP). The significance of this approval is that Dupixent is the first and only targeted medicine to treat BP, a rare and debilitating blistering skin disease, and offers a more specific and safer treatment alternative to traditional therapies. (Source: Sanofi)

Why is Asia Pacific Significantly Growing in the Dupixent Market?

Asia Pacific expects significant growth in the Dupixent market during the forecast period. There is a high and growing prevalence of chronic diseases, creating a large patient base for Dupixent. The region has a large patient population suffering from conditions treated by Dupixent, expansion of therapeutic indications, and patient groups. The increasing healthcare expenditure and development of advanced healthcare infrastructure delivery of specific drugs. 

• In March 2025, Japan's Ministry of Health, Labour and Welfare also granted marketing approval for Dupixent for uncontrolled COPD. This was the first new treatment approach for the condition in Japan in over a decade. (Source: Sanofi) 

Segmental Insights

Indication Insights

Why did the Atopic Dermatitis (AD) Segment Dominate the Dupixent Market?

The atopic dermatitis (AD) segment held the leading position in the market in 2024, capturing the highest revenue share of 74% in 2024. The long-term observation study shows that Dupixent benefits are sustained over a year of treatment. The dermatologist and dermatologists playing a central role in managing moderate-to-severe AD, high awareness of Dupixent's effectiveness drives a strong participation rate. Global market reports note that dermatologists prefer Duplixent for its strong clinical profile.

•  In June 2025, new Phase 4 data from the DISCOVER trial reinforced Dupixent's efficacy and safety in adult and adolescent AD patients with darker skin tones. The results addressed an underserved population and showed positive outcomes on dyspigmentation and dry skin. (Source: Sanofi) 

The chronic obstructive pulmonary disease (COPD) segment is the fastest-growing in the Dupixent market during the forecast period. The growing number of diagnosed cases, due to an aging population and environmental risk factors, such as air pollution and smoking, creates a larger patient pool for treatment like Dupixent. The increasing awareness among pulmonologists about Dupixent's benefits and real-world success stories is driving demand for this targeted therapy. It offers a novel mechanism of action, a high unmet need, and boosts market growth.
In July 2024, the European Medicines Agency approved Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD and a history of raised blood eosinophils. This first-in-the-world approval was a major catalyst for the COPD market.  (Source: Sanofi)  

Distribution Channel Insights

How the Hospital Pharmacies Segment hold the Largest Share in the Dupixent Market?

The hospital pharmacies led the Dupixent market, accounting for the highest revenue share of 54% in 2024. Dupixent is a high-cost biological medication that often requires specialized handling, storage, and precise dosing. Many patients start Dupixent therapy under the close supervision of specialists in a hospital setting. This ensures proper evaluation, administration techniques (such as subcutaneous injection training), and initial monitoring for potential side effects. It is multidisciplinary care an established reimbursement pathway and stock management, and focuses on acute care and exacerbations. 

The other segment is experiencing the fastest growth in the market during the forecast period. The more patients seek treatment in outpatient and home care settings, the demand for flexible and suitable access to biologics is growing. Specialty and mail-order pharmacies, in particular, offer services such as insurance coordination, home delivery, and patient support programs, making Dupixent more accessible for long-term use.

The Dupixent Market-Value Chain Analysis

• R&D: The Dupixent market focuses on targeting the central IL-4 and IL-13 pathways, demonstrating significant clinical benefits and leading to regulatory approvals for various patient populations. 
• Patient Support and Services: The Dupixent market contains navigating insurance, finding alternative funding, and connecting patients with resources for financial assistance and reimbursement support, primarily through Sanofi US's patient support programs.  
• Distribution to Hospitals, Pharmacies: The primary distribution is through hospital pharmacies. Other retail and online pharmacies. 

Recent Developments

• In April 2025, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) as the first new targeted therapy in over a decade for chronic spontaneous urticaria (CSU). This approval is for adults and adolescents (12 years and older) whose symptoms persist despite standard treatment with antihistamines. (Source: Sanofi)  
• In April 2025, Regeneron announced a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its large-scale manufacturing capacity in the US. (Source: REGENERON) 

Top Companies in Dupixent Market

• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• GlaxoSmithKline plc (GSK) 
• Novartis AG 
• AstraZeneca plc 
• Eli Lilly and Company
• AbbVie Inc.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.

Market Segmentation

By Indication 

• Atopic Dermatitis (AD)
• Asthma
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
• Chronic Obstructive Pulmonary Disease (COPD)
• Others

By Distribution Channel 

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Regional

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait